Ambrx Inc - Company & Market Research Reports

Ambrx is a biopharmaceutical company that produces protein therapeutics which reduce frequency of dosing, and optimizes efficiency and safety. Ambrx, Inc. was founded in 2003 and is based in La Jolla, California. The company collaborates with Mabspace Biosciences for oncology purposes in China and internationally. They develop a range of products such as ADC, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs.


Monoclonal Antibodies Market: By Application [Oncology, Autoimmune and inflammatory diseases, Respiratory diseases and Ophthalmology] & By Geography - Forecast 2016-2021 - Product Thumbnail Image

Monoclonal Antibodies Market: By Application [Oncology, Autoimmune and inflammatory diseases, Respiratory diseases and Ophthalmology] & By Geography - Forecast 2016-2021

  • Report
  • 135 Pages
From
Report package: T-Cell Immunotherapy by Bispecific Antibodies and CAR & TCR Engineered T-cells - Product Thumbnail Image

Report package: T-Cell Immunotherapy by Bispecific Antibodies and CAR & TCR Engineered T-cells

  • Report
  • 618 Pages
From
Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors - Product Thumbnail Image

Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors

  • Report
  • 58 Pages
From
Bispecific Antibodies: Clinical Trial Tracker - Product Thumbnail Image

Bispecific Antibodies: Clinical Trial Tracker

  • Clinical Trials
From
T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals - Product Thumbnail Image

T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals

  • Report
  • 230 Pages
From
Metastatic Breast Cancer - Pipeline Review, H2 2016 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Review, H2 2016

  • Report
  • 1096 Pages
From
Breast Cancer - Pipeline Review, H2 2016 - Product Thumbnail Image

Breast Cancer - Pipeline Review, H2 2016

  • Report
  • 3149 Pages
From
Breast Cancer - Pipeline Review, H1 2016 - Product Thumbnail Image

Breast Cancer - Pipeline Review, H1 2016

  • Report
  • 3011 Pages
From
Metastatic Breast Cancer - Pipeline Review, H1 2016 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Review, H1 2016

  • Report
  • 1079 Pages
From
Metastatic Breast Cancer - Pipeline Review, H2 2015 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Review, H2 2015

  • Report
  • 966 Pages
From
Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012 to 2018 - Product Thumbnail Image

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012 to 2018

  • Report
  • 457 Pages
From
Immune Checkpoint Inhibitors: Clinical Trial Tracker - Product Thumbnail Image

Immune Checkpoint Inhibitors: Clinical Trial Tracker

  • Clinical Trials
From
Antibody Drug Conjugates: Clinical Trial Tracker - Product Thumbnail Image

Antibody Drug Conjugates: Clinical Trial Tracker

  • Clinical Trials
From
Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

  • Report
  • 244 Pages
From
Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 - Product Thumbnail Image

Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020

  • Drug Pipelines
  • 240 Pages
From
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016 - Product Thumbnail Image

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016

  • Report
  • 116 Pages
From
Renal Cell Carcinoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Renal Cell Carcinoma - Pipeline Review, H2 2016

  • Report
  • 793 Pages
From
Renal Cell Carcinoma - Pipeline Review, H1 2016 - Product Thumbnail Image

Renal Cell Carcinoma - Pipeline Review, H1 2016

  • Report
  • 811 Pages
From
Renal Cell Carcinoma - Pipeline Review, H1 2015 - Product Thumbnail Image

Renal Cell Carcinoma - Pipeline Review, H1 2015

  • Report
  • 609 Pages
From
Ovarian Cancer - Pipeline Review, H2 2017 - Product Thumbnail Image

Ovarian Cancer - Pipeline Review, H2 2017

  • Report
  • 2232 Pages
From
Loading Indicator
adroll